CREATE Medicines is a Cambridge, Massachusetts clinical-stage biotech building in vivo immune programming - therapies that use an mRNA-lipid nanoparticle platform to turn a patient's own T cells, NK cells, and myeloid cells into chimeric antigen receptor (CAR) cells directly inside the body, rather than extracting and re-engineering them in a lab. Formerly Myeloid Therapeutics, the company rebranded in October 2025 as its pipeline expanded beyond myeloid cells and cancer into autoimmune disease and fibrosis. Its repeat-dosable, off-the-shelf approach aims to make CAR therapy cheaper and more scalable than conventional cell therapy, and the company says it has dosed more than 50 patients - among the largest clinical datasets for in vivo CAR to date.
Kytopen is a Cambridge, Massachusetts biotech and MIT spinout building Flowfect, a non-viral, continuous-flow platform that uses fluid flow plus electric fields to deliver mRNA, DNA and CRISPR payloads into cells. The technology aims to engineer hundreds of billions of cells in minutes, removing a major bottleneck in discovering, developing and manufacturing advanced cell therapies like CAR-T and NK-cell treatments.